PMID- 25201464
OWN - NLM
STAT- MEDLINE
DCOM- 20141208
LR  - 20220331
IS  - 1879-0852 (Electronic)
IS  - 0959-8049 (Linking)
VI  - 50
IP  - 16
DP  - 2014 Nov
TI  - Metformin significantly reduces incident prostate cancer risk in Taiwanese men 
      with type 2 diabetes mellitus.
PG  - 2831-7
LID - S0959-8049(14)00886-7 [pii]
LID - 10.1016/j.ejca.2014.08.007 [doi]
AB  - BACKGROUND: Whether metformin therapy affects incident prostate cancer risk in 
      Asian patients with type 2 diabetes mellitus (T2DM) has not been investigated. 
      METHODS: The National Health Insurance reimbursement database of Taiwanese male 
      patients with new-onset T2DM between 1998 and 2002 and aged ⩾40years (n=395,481) 
      were retrieved to follow up prostate cancer incidence until the end of 2009. 
      Metformin was treated as a time-dependent variable. Of the patients studied, 
      209,269 were never-users and 186,212 were ever-users. A time-dependent approach 
      was used to calculate prostate cancer incidence and estimate hazard ratios using 
      Cox regression for ever-users, never-users and subgroups of metformin exposure 
      (tertiles of cumulative duration and cumulative dose). Sensitivity analyses were 
      conducted in various subgroups, using time-dependent and non-time-dependent 
      approaches. RESULTS: During the follow-up, 2776 metformin ever-users and 9642 
      never-users developed prostate cancer, representing an incidence of 239.42 and 
      737.10 per 100,000 person-years, respectively. The hazard ratio (95% confidence 
      intervals) after adjustment for propensity score (PS) for ever- versus 
      never-users was 0.467 (0.446-0.488). The PS-adjusted hazard ratios for the first, 
      second and third tertiles of cumulative duration of metformin therapy were 0.741 
      (0.698-0.786), 0.474 (0.441-0.508) and 0.231 (0.212-0.253), respectively 
      (P-trend<0.001); and were 0.742 (0.700-0.786), 0.436 (0.406-0.468) and 0.228 
      (0.208-0.251) for the respective cumulative dose (P-trend<0.001). Sensitivity 
      analyses consistently supported a protective effect of metformin on incident 
      prostate cancer. CONCLUSIONS: Metformin use is associated with a decreased risk 
      of incident prostate cancer in Taiwanese male patients with T2DM.
CI  - Copyright (c) 2014 Elsevier Ltd. All rights reserved.
FAU - Tseng, Chin-Hsiao
AU  - Tseng CH
AD  - Department of Internal Medicine, National Taiwan University College of Medicine, 
      Taipei, Taiwan; Division of Endocrinology and Metabolism, Department of Internal 
      Medicine, National Taiwan University Hospital, Taipei, Taiwan; Division of 
      Environmental Health and Occupational Medicine of the National Health Research 
      Institutes, Taipei, Taiwan. Electronic address: ccktsh@ms6.hinet.net.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140905
PL  - England
TA  - Eur J Cancer
JT  - European journal of cancer (Oxford, England : 1990)
JID - 9005373
RN  - 0 (Hypoglycemic Agents)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Diabetes Complications/*drug therapy/prevention & control
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Incidence
MH  - Male
MH  - Metformin/*therapeutic use
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Prostatic Neoplasms/*complications/prevention & control
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Taiwan
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Diabetes
OT  - Epidemiology
OT  - Metformin
OT  - Prostate cancer
OT  - Taiwan
EDAT- 2014/09/10 06:00
MHDA- 2014/12/15 06:00
CRDT- 2014/09/10 06:00
PHST- 2014/03/24 00:00 [received]
PHST- 2014/07/08 00:00 [revised]
PHST- 2014/08/05 00:00 [accepted]
PHST- 2014/09/10 06:00 [entrez]
PHST- 2014/09/10 06:00 [pubmed]
PHST- 2014/12/15 06:00 [medline]
AID - S0959-8049(14)00886-7 [pii]
AID - 10.1016/j.ejca.2014.08.007 [doi]
PST - ppublish
SO  - Eur J Cancer. 2014 Nov;50(16):2831-7. doi: 10.1016/j.ejca.2014.08.007. Epub 2014 
      Sep 5.